Decationized polyplexes for gene delivery

L. Novo, E. Mastrobattista, C.F. van Nostrum, Twan Gerardus Gertudis Maria Lammers, W.E. Hennink

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)

Abstract

Gene therapy has received much attention in the field of drug delivery. Synthetic, nonviral gene delivery systems have gained increasing attention as vectors for gene therapy mainly due to a favorable immunogenicity profile and ease of manufacturing as compared to viral vectors. The great majority of these formulations are based on polycationic structures, due to their ability to interact with negatively charged nucleic acids to spontaneously form nanoparticles. In recent years, several polycationic systems have demonstrated high transfection in vitro. However, progress toward clinical applications has been slow, mainly because the cationic nature of these systems leads to intolerable toxicity levels, inappropriate biodistribution and unsatisfactory efficiency in vivo, particularly after systemic administration. Decationized polyplexes are a new class of gene delivery systems that have been developed as an alternative for conventional polycation-based systems. The major innovation introduced by decationized polyplexes is that these systems are based on neutral polymers, without any detrimental effect on the physicochemical stability or encapsulation ability, due to the transient presence of cationic charge and disulfide cross-links between the polymer chains by which the nucleic acids are physically entrapped in the particles. This editorial summarizes the most important features of decationized polyplexes and discusses potential implications for the development of new safe and efficient gene delivery systems.
Original languageUndefined
Pages (from-to)507-512
JournalExpert opinion on drug delivery
Volume12
Issue number4
DOIs
Publication statusPublished - 2015

Keywords

  • METIS-315274
  • IR-99949

Cite this

Novo, L., Mastrobattista, E., van Nostrum, C. F., Lammers, T. G. G. M., & Hennink, W. E. (2015). Decationized polyplexes for gene delivery. Expert opinion on drug delivery, 12(4), 507-512. https://doi.org/10.1517/17425247.2015.988136
Novo, L. ; Mastrobattista, E. ; van Nostrum, C.F. ; Lammers, Twan Gerardus Gertudis Maria ; Hennink, W.E. / Decationized polyplexes for gene delivery. In: Expert opinion on drug delivery. 2015 ; Vol. 12, No. 4. pp. 507-512.
@article{038611cb4cf048c3a517419ea2867202,
title = "Decationized polyplexes for gene delivery",
abstract = "Gene therapy has received much attention in the field of drug delivery. Synthetic, nonviral gene delivery systems have gained increasing attention as vectors for gene therapy mainly due to a favorable immunogenicity profile and ease of manufacturing as compared to viral vectors. The great majority of these formulations are based on polycationic structures, due to their ability to interact with negatively charged nucleic acids to spontaneously form nanoparticles. In recent years, several polycationic systems have demonstrated high transfection in vitro. However, progress toward clinical applications has been slow, mainly because the cationic nature of these systems leads to intolerable toxicity levels, inappropriate biodistribution and unsatisfactory efficiency in vivo, particularly after systemic administration. Decationized polyplexes are a new class of gene delivery systems that have been developed as an alternative for conventional polycation-based systems. The major innovation introduced by decationized polyplexes is that these systems are based on neutral polymers, without any detrimental effect on the physicochemical stability or encapsulation ability, due to the transient presence of cationic charge and disulfide cross-links between the polymer chains by which the nucleic acids are physically entrapped in the particles. This editorial summarizes the most important features of decationized polyplexes and discusses potential implications for the development of new safe and efficient gene delivery systems.",
keywords = "METIS-315274, IR-99949",
author = "L. Novo and E. Mastrobattista and {van Nostrum}, C.F. and Lammers, {Twan Gerardus Gertudis Maria} and W.E. Hennink",
year = "2015",
doi = "10.1517/17425247.2015.988136",
language = "Undefined",
volume = "12",
pages = "507--512",
journal = "Expert opinion on drug delivery",
issn = "1742-5247",
publisher = "Taylor & Francis",
number = "4",

}

Novo, L, Mastrobattista, E, van Nostrum, CF, Lammers, TGGM & Hennink, WE 2015, 'Decationized polyplexes for gene delivery' Expert opinion on drug delivery, vol. 12, no. 4, pp. 507-512. https://doi.org/10.1517/17425247.2015.988136

Decationized polyplexes for gene delivery. / Novo, L.; Mastrobattista, E.; van Nostrum, C.F.; Lammers, Twan Gerardus Gertudis Maria; Hennink, W.E.

In: Expert opinion on drug delivery, Vol. 12, No. 4, 2015, p. 507-512.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Decationized polyplexes for gene delivery

AU - Novo, L.

AU - Mastrobattista, E.

AU - van Nostrum, C.F.

AU - Lammers, Twan Gerardus Gertudis Maria

AU - Hennink, W.E.

PY - 2015

Y1 - 2015

N2 - Gene therapy has received much attention in the field of drug delivery. Synthetic, nonviral gene delivery systems have gained increasing attention as vectors for gene therapy mainly due to a favorable immunogenicity profile and ease of manufacturing as compared to viral vectors. The great majority of these formulations are based on polycationic structures, due to their ability to interact with negatively charged nucleic acids to spontaneously form nanoparticles. In recent years, several polycationic systems have demonstrated high transfection in vitro. However, progress toward clinical applications has been slow, mainly because the cationic nature of these systems leads to intolerable toxicity levels, inappropriate biodistribution and unsatisfactory efficiency in vivo, particularly after systemic administration. Decationized polyplexes are a new class of gene delivery systems that have been developed as an alternative for conventional polycation-based systems. The major innovation introduced by decationized polyplexes is that these systems are based on neutral polymers, without any detrimental effect on the physicochemical stability or encapsulation ability, due to the transient presence of cationic charge and disulfide cross-links between the polymer chains by which the nucleic acids are physically entrapped in the particles. This editorial summarizes the most important features of decationized polyplexes and discusses potential implications for the development of new safe and efficient gene delivery systems.

AB - Gene therapy has received much attention in the field of drug delivery. Synthetic, nonviral gene delivery systems have gained increasing attention as vectors for gene therapy mainly due to a favorable immunogenicity profile and ease of manufacturing as compared to viral vectors. The great majority of these formulations are based on polycationic structures, due to their ability to interact with negatively charged nucleic acids to spontaneously form nanoparticles. In recent years, several polycationic systems have demonstrated high transfection in vitro. However, progress toward clinical applications has been slow, mainly because the cationic nature of these systems leads to intolerable toxicity levels, inappropriate biodistribution and unsatisfactory efficiency in vivo, particularly after systemic administration. Decationized polyplexes are a new class of gene delivery systems that have been developed as an alternative for conventional polycation-based systems. The major innovation introduced by decationized polyplexes is that these systems are based on neutral polymers, without any detrimental effect on the physicochemical stability or encapsulation ability, due to the transient presence of cationic charge and disulfide cross-links between the polymer chains by which the nucleic acids are physically entrapped in the particles. This editorial summarizes the most important features of decationized polyplexes and discusses potential implications for the development of new safe and efficient gene delivery systems.

KW - METIS-315274

KW - IR-99949

U2 - 10.1517/17425247.2015.988136

DO - 10.1517/17425247.2015.988136

M3 - Article

VL - 12

SP - 507

EP - 512

JO - Expert opinion on drug delivery

JF - Expert opinion on drug delivery

SN - 1742-5247

IS - 4

ER -